For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo Launches Antiplatelet Agent Efient® Tablets 20mg

TOKYO, Japan (May 25, 2016) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched the antiplatelet agent Efient^® Tablets 20mg  (JAN: Prasugrel Hydrochloride; approval to market: January 20, 2016; NHI drug price listing: May 25, 2016) in Japan.

 

Efient^® is an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Limited. The results of phase 3 clinical trials in domestic and overseas patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI) demonstrated that Efient^® reduces the incidence of ischemic events from the perioperative period of PCI by rapidly reducing platelet aggregation activity.

 

Domestically, Efient^® Tablets have been sold in 3.75mg/5mg dosages since May 2014. Under the current dosage regimen, Efient^® should be initiated with a single 20mg oral dose, and then continued at a 3.75mg once daily oral dose as a maintenance dose.

 

Under the current dosage regime, four 5mg tablets have been used for the initial loading dose, leading to this introduction of a single 20mg tablet. Daiichi Sankyo expects that reducing the burden at the time of use for this drug will contribute to a higher level of care for all patients and medical personnel involved in the treatment of ischemic heart diseases.

 

 

 

Product Overview in Japan

 

Launch date: May 25, 2016